{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:44:38Z","timestamp":1791042278337,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1331\/154434506778073637","type":"journal-article","created":{"date-parts":[[2006,8,19]],"date-time":"2006-08-19T08:41:55Z","timestamp":1155976915000},"page":"479-490","source":"Crossref","is-referenced-by-count":40,"title":["Safety Issues with Statin Therapy"],"prefix":"10.1016","volume":"46","author":[{"given":"Robert L.","family":"Talbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1331\/154434506778073637_bb0010","series-title":"American Heart Association. Heart disease and stroke statistics\u20142005 update","year":"2005"},{"key":"10.1331\/154434506778073637_bb0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/hc0202.101971","article-title":"New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population","volume":"105","author":"Fedder","year":"2002","journal-title":"Circulation"},{"key":"10.1331\/154434506778073637_bb0020","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1331\/154434506778073637_bb0025","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1331\/154434506778073637_bb0030","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1331\/154434506778073637_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1331\/154434506778073637_bb0040","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1331\/154434506778073637_bb0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1331\/154434506778073637_bb0050","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"10.1331\/154434506778073637_bb0055","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","article-title":"Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients","volume":"92","author":"Newman","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1331\/154434506778073637_bb0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1331\/154434506778073637_bb0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"suppl III","key":"10.1331\/154434506778073637_bb0070","first-page":"III-50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1331\/154434506778073637_bb0075","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/archinte.160.15.2273","article-title":"Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism\u2014monograph for physicians","volume":"160","author":"Bottorff","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1331\/154434506778073637_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1331\/154434506778073637_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1076-7460.2002.01422.x","article-title":"Rhabdomyolysis and statin therapy: relevance to the elderly","volume":"11","author":"Sica","year":"2002","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1331\/154434506778073637_bb0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1331\/154434506778073637_bb0095","doi-asserted-by":"crossref","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","article-title":"Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyulglutaryl coenzyme A reductase inhibitor","volume":"87","author":"McTaggart","year":"2001","journal-title":"A M Cardiol"},{"key":"10.1331\/154434506778073637_bb0100","series-title":"Crestor [package insert]","year":"2005"},{"key":"10.1331\/154434506778073637_bb0105","series-title":"Lescol [package insert]","year":"2003"},{"key":"10.1331\/154434506778073637_bb0110","series-title":"Lipitor [package insert]","year":"2004"},{"key":"10.1331\/154434506778073637_bb0115","series-title":"Pravachol [package insert]","year":"2004"},{"key":"10.1331\/154434506778073637_bb0120","series-title":"Zocor [package insert]","year":"2004"},{"key":"10.1331\/154434506778073637_bb0125","first-page":"75","article-title":"Pharmacogenomics","author":"Cavallari","year":"2005"},{"key":"10.1331\/154434506778073637_bb0130","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1331\/154434506778073637_bb0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2000.104391","article-title":"CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity","volume":"67","author":"Sata","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/154434506778073637_bb0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","article-title":"Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution","volume":"7","author":"Marez","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1331\/154434506778073637_bb0145","first-page":"339","article-title":"Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis","volume":"94","author":"Kanathur","year":"2001","journal-title":"Tennessee Med"},{"key":"10.1331\/154434506778073637_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1567-5688(02)00002-8","article-title":"Pharmacological interactions of statins","volume":"3","author":"Paoletti","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"10.1331\/154434506778073637_bb0155","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/oxfordjournals.ndt.a027682","article-title":"Drug-interaction-induced rhabdomyolysis","volume":"11","author":"Segaert","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1331\/154434506778073637_bb0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w1","article-title":"Potentially fatal interaction between diltiazem and statins","volume":"140","author":"Gladding","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1331\/154434506778073637_bb0165","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/ajhp\/62.9.905","article-title":"Telithromycin: the first ketolide for the treatment of respiratory infection","volume":"62","author":"Kasbekar","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1331\/154434506778073637_bb0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","article-title":"Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy","volume":"28","author":"R\u00e4tz Bravo","year":"2005","journal-title":"Drug Saf"},{"key":"10.1331\/154434506778073637_bb0175","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0149-2918(02)80102-3","article-title":"An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study","volume":"24","author":"Einarson","year":"2002","journal-title":"Clin Ther"},{"key":"10.1331\/154434506778073637_bb0180","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1001\/archinte.163.19.2394","article-title":"Possible differences between fibrates in pharmacokinetic interactions with statins [letter]","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1331\/154434506778073637_bb0185","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1331\/154434506778073637_bb0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/154434506778073637_bb0195","doi-asserted-by":"crossref","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","article-title":"A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters","volume":"274","author":"Hsiang","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1331\/154434506778073637_bb0200","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2003.12.016","article-title":"Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics","volume":"75","author":"Mwinyi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/154434506778073637_bb0205","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/154434506778073637_bb0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/154434506778073637_bb0215","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0149-2918(03)80089-9","article-title":"An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1331\/154434506778073637_bb0220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1331\/154434506778073637_bb0225","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1097\/00007890-200206270-00022","article-title":"Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine","volume":"73","author":"Vlahakos","year":"2002","journal-title":"Transplantation"},{"key":"10.1331\/154434506778073637_bb0230","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/01.TP.0000085287.03333.FC","article-title":"Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient","volume":"76","author":"Barshes","year":"2003","journal-title":"Transplantation"},{"key":"10.1331\/154434506778073637_bb0235","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1592\/phco.2005.25.7.918","article-title":"Retrospective analysis of hyperlipidemia management in a transplant population","volume":"25","author":"Schonder","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1331\/154434506778073637_bb0240","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archinte.163.6.688","article-title":"Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting","volume":"163","author":"Smith","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1331\/154434506778073637_bb0245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinte.163.6.657","article-title":"Safety and statin therapy: reconsidering the risks and benefits","volume":"163","author":"Gotto","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1331\/154434506778073637_bb0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-CoA reductase inhibitors","volume":"23","author":"Farmer","year":"2000","journal-title":"Drug Saf"},{"key":"10.1331\/154434506778073637_bb0255","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/pds.832","article-title":"Liver function testing in patients on HMG-CoA reductase inhibitors","volume":"12","author":"Andrade","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1331\/154434506778073637_bb0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3949\/ccjm.55.1.93","article-title":"HMG-CoA reductase inhibitors: a new approach to the management of hypercholesterolemia","volume":"55","author":"Cressman","year":"1988","journal-title":"Cleve Clin J Med"},{"key":"10.1331\/154434506778073637_bb0265","series-title":"Vytorin [package insert]","year":"2005"},{"key":"10.1331\/154434506778073637_bb0270","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11883-002-0060-0","article-title":"A general assessment of the safety of HMG CoA reductase inhibitors (statins)","volume":"4","author":"Black","year":"2002","journal-title":"Curr Atheroscler Rep"},{"key":"10.1331\/154434506778073637_bb0275","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1001\/archinte.159.15.1811-a","article-title":"Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus","volume":"159","author":"Jimenez-Alonso","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1331\/154434506778073637_bb0280","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00042737-200308000-00014","article-title":"Autoimmune hepatitis revealed by atorvastatin","volume":"15","author":"Pelli","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1331\/154434506778073637_bb0285","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1331\/154434506778073637_bb0290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14740338.2.3.269","article-title":"Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era","volume":"2","author":"Jacobson","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"10.1331\/154434506778073637_bb0295","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/mus.10053","article-title":"Rhabdomyolysis: a review","volume":"25","author":"Warren","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1331\/154434506778073637_bb0300","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jclinepi.2004.10.004","article-title":"Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis","volume":"58","author":"Andrade","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1331\/154434506778073637_bb0305","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1331\/154434506778073637_bb0310","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1345\/aph.1A289","article-title":"FDA adverse event reports on statin-associated rhabdomyolysis","volume":"36","author":"Omar","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1331\/154434506778073637_bb0315","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1331\/154434506778073637_bb0320","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1331\/154434506778073637_bb0325","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"},{"key":"10.1331\/154434506778073637_bb0330","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0002-9149(01)01464-3","article-title":"Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin","volume":"87","author":"Downs","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1331\/154434506778073637_bb0335","series-title":"Food and Drug Administration. FDA response to a citizen petition regarding Crestor (March 11, 2005)","year":"2005"},{"issue":"suppl 10B","key":"10.1331\/154434506778073637_bb0340","doi-asserted-by":"crossref","first-page":"50K","DOI":"10.1016\/S0002-9149(02)02970-3","article-title":"Combination therapy for dyslipidemia: safety and regulatory considerations","volume":"90","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1331\/154434506778073637_bb0345","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0098-2997(97)00014-9","article-title":"Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors","volume":"18","author":"Mortensen","year":"1997","journal-title":"Mol Aspects Med"},{"key":"10.1331\/154434506778073637_bb0350","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1331\/154434506778073637_bb0355","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","article-title":"Rosuvastatin safety: lessons from the FDA review and post-approval surveillance","volume":"3","author":"Davidson","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1331\/154434506778073637_bb0360","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1097\/01.ASN.0000143720.71748.79","article-title":"Statin induced proteinuria: renal injury or renoprotection?","volume":"15","author":"Agarwal","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1331\/154434506778073637_bb0365","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.58.9.1333","article-title":"Statins and risk of polyneuropathy: a case-control study","volume":"58","author":"Gaist","year":"2002","journal-title":"Neurology"},{"key":"10.1331\/154434506778073637_bb0370","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/sleep\/22.1.117","article-title":"Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects","volume":"22","author":"Ehrenberg","year":"1999","journal-title":"Sleep"},{"key":"10.1331\/154434506778073637_bb0375","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00392-004-1003-2","article-title":"Does statin therapy influence steroid hormone synthesis?","volume":"93","author":"Bohm","year":"2004","journal-title":"Z Kardiol"},{"key":"10.1331\/154434506778073637_bb0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2710.2003.00540.x","article-title":"Hormonal changes with cholesterol reduction: a double-blind pilot study","volume":"29","author":"Ormiston","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"10.1331\/154434506778073637_bb0385","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 8A","key":"10.1331\/154434506778073637_bb0390","first-page":"1C","article-title":"A symposium: report of the National Lipid Association's Statin Safety Task Force","volume":"97","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319115315077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319115315077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T15:18:18Z","timestamp":1555773498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319115315077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1544319115315077"],"URL":"https:\/\/doi.org\/10.1331\/154434506778073637","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}